Some price data may be temporarily unavailable.
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
Organovo Holdings, Inc. is engaged in the development of bioprinted human tissues that emulate human biology and disease. Its three-dimensional human tissue platform is enabled by its proprietary NovoGen Bioprinters and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company was founded on January 30, 2012 and is headquartered in San Diego, CA.
The company's licensing agreement with a Swedish company means an infusion of some much-needed cash for Organovo.
The tissue engineering company reported fiscal fourth-quarter and full-year 2018 results.
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
